EyePoint Pharmaceuticals

EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet AMD, the leading cause of vision loss among people 50 years of age and older in the United States. EyePoint’s product candidate pipeline also includes YUTIQ® 50, a potential twice-yearly treatment for non-infectious uveitis affecting the posterior segment of the eye, and separately, two commercial products, YUTIQ and DEXYCU.

Visit sponsor site


To view all of our sponsors, please click here